Keros Therapeutics (KROS) Common Equity (2019 - 2026)

Keros Therapeutics (KROS) has reported Common Equity for 8 consecutive years, with $262.3 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Common Equity fell 62.88% year-over-year to $262.3 million; the trailing twelve-month figure through Jun 2026 stood at $262.3 million (down 62.88% YoY), and the FY2025 full-year result was $303.1 million, down 46.96% from the prior year.
• Common Equity slipped to $262.3 million in Q2 2026 per KROS's latest filing, from $303.1 million in the prior quarter.
• Across five years, Common Equity topped out at $728.9 million in Q1 2025 and bottomed at $211.2 million in Q2 2022.
• Historically, Common Equity has averaged $408.6 million across 5 years, with a median of $332.2 million in 2023.
• The sharpest annual moves came in 2024 and 2026: Common Equity surged 80.11% in 2024, then tumbled 62.88% in 2026.
• Over 5 years, Common Equity stood at $277.4 million in 2022, then grew by 19.75% to $332.2 million in 2023, then soared by 72.04% to $571.6 million in 2024, then plunged by 46.96% to $303.1 million in 2025, then dropped by 13.46% to $262.3 million in 2026.
• According to Business Quant data, Common Equity over the past three periods registered $262.3 million, $303.1 million, and $703.6 million for Q2 2026, Q4 2025, and Q3 2025 respectively.